Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation

Medical University of Vienna100 enrolled

Overview

Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.

Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Evidence of Liver Transplantation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * End stage liver disease, chronic liver failure, orthotopic liver transplantation Exclusion Criteria: * Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure

Locations (1)

Medical University Vienna

Vienna, Austria

Outcomes

Primary Outcomes

Macrophage Migration Inhibitory Factor in human serum, liver graft effluent and urine

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.